180 Life Sciences Corp (ATNF)
1.68
-0.07
(-4.00%)
USD |
NASDAQ |
Sep 27, 16:00
1.71
+0.03
(+1.79%)
After-Hours: 20:00
180 Life Sciences Cash from Financing (Quarterly): -0.2649M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.2649M |
| March 31, 2024 | -0.2644M |
| December 31, 2023 | 1.468M |
| September 30, 2023 | 2.447M |
| June 30, 2023 | 2.462M |
| March 31, 2023 | -0.4698M |
| December 31, 2022 | 6.396M |
| September 30, 2022 | 5.488M |
| June 30, 2022 | -0.4943M |
| Date | Value |
|---|---|
| March 31, 2022 | -0.5154M |
| December 31, 2021 | 1.549M |
| September 30, 2021 | 13.73M |
| June 30, 2021 | -0.2285M |
| March 31, 2021 | 10.36M |
| December 31, 2020 | -9.226M |
| September 30, 2020 | 0.1468M |
| June 30, 2020 | 0.0115M |
| March 31, 2020 | 0.3334M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-9.226M
Minimum
Dec 2020
13.73M
Maximum
Sep 2021
1.830M
Average
0.2401M
Median
Cash from Financing (Quarterly) Benchmarks
| Seelos Therapeutics Inc | 0.742M |
| NovaBay Pharmaceuticals Inc | -0.492M |
| Palatin Technologies Inc | 9.136M |
| iBio Inc | 12.99M |
| Theriva Biologics Inc | 1.773M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 0.7272M |
| Free Cash Flow | -4.242M |
| Free Cash Flow Per Share (Quarterly) | 0.7911 |
| Free Cash Flow Yield | -402.2% |